Analyst Price Targets — XFOR
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| December 5, 2025 11:37 am | James Condulis | Stifel Nicolaus | $10.00 | $3.80 | TheFly | X4 Pharmaceuticals price target raised to $10 from $7.50 at Stifel |
| November 5, 2025 5:17 pm | Stephen Willey | Stifel Nicolaus | $7.50 | $3.60 | StreetInsider | X4 Pharmaceuticals (XFOR) PT Lowered to $7.50 at Stifel |
| August 29, 2025 11:57 am | Stephen Willey | Stifel Nicolaus | $9.00 | $3.87 | TheFly | X4 Pharmaceuticals price target lowered to $9 from $30 at Stifel |
| August 13, 2025 10:12 am | Swayampakula Ramakanth | H.C. Wainwright | $3.50 | $2.58 | TheFly | X4 Pharmaceuticals price target lowered to $3.50 from $7 at H.C. Wainwright |
| December 22, 2022 6:43 am | — | Cantor Fitzgerald | $3.00 | $0.85 | Benzinga | Cantor Fitzgerald Initiates Coverage On X4 Pharmaceuticals with Overweight Rating, Announces Price Target of $3 |
| December 11, 2022 5:05 pm | Edward Tenthoff | Piper Sandler | $3.00 | $0.93 | TheFly | X4 Pharmaceuticals initiated with an Overweight at Piper Sandler |
| November 30, 2022 6:30 am | — | H.C. Wainwright | $5.00 | $1.85 | Benzinga | HC Wainwright & Co. Maintains Buy on X4 Pharmaceuticals, Raises Price Target to $5 |
Latest News for XFOR
Analyst sentiment across three small-cap biotechs has turned notably positive, with fresh coverage initiations and maintained Buy-equivalent ratings from institutional research desks ahead of 2026 clinical catalysts.
BOSTON, March 04, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that the management team will participate in a fireside chat at the Leerink Global Healthcare Conference on Wednesday, March 11, 2026 at 10:00 a.m. ET in Miami, FL.
X4 Pharmaceuticals (XFOR) is rated BUY, driven by a funded Phase 3 trial, current product pipeline, and a strong cash position extending into 2028. XFOR's primary value lies in its 4WARD Phase 3 trial in chronic neutropenia, targeting a US market of ~15,000 patients, with a pivotal Phase 3 readout expected within 12–18 months. Recent restructuring cut costs, strengthened the balance sheet, and mitigated near-term…
BOSTON, March 02, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on February 27, 2026, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for…
- Potential First and Only Therapy in the EU for Ultra-Rare Immune Disorder - BOSTON, Feb. 27, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of marketing…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for XFOR.
U.S. House Trading
No House trades found for XFOR.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.